Technical Analysis for GNFT - GENFIT S.A.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 4.00 | 10.80% | 0.39 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 200 DMA | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 200 DMA | Bearish | 10.80% | |
Wide Bands | Range Expansion | 10.80% | |
Gapped Down | Weakness | 10.80% | |
Oversold Stochastic | Weakness | 10.80% | |
Wide Bands | Range Expansion | 3.63% | |
Gapped Up | Strength | 3.63% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 5 hours ago |
Rose Above 10 DMA | about 5 hours ago |
Up 10% | about 5 hours ago |
Up 1 ATR | about 5 hours ago |
Gapped Up (Full) | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/22/2024
GENFIT S.A. Description
GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Alcohol Autoimmune Disease Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Hepatology Liver Diagnostic Solutions Primary Biliary Cholangitis Chronic Liver Disease Clinical Management
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.05 |
52 Week Low | 2.8935 |
Average Volume | 27,917 |
200-Day Moving Average | 3.67 |
50-Day Moving Average | 4.17 |
20-Day Moving Average | 4.51 |
10-Day Moving Average | 3.91 |
Average True Range | 0.29 |
RSI (14) | 45.05 |
ADX | 29.98 |
+DI | 23.97 |
-DI | 31.27 |
Chandelier Exit (Long, 3 ATRs) | 5.18 |
Chandelier Exit (Short, 3 ATRs) | 4.48 |
Upper Bollinger Bands | 5.89 |
Lower Bollinger Band | 3.14 |
Percent B (%b) | 0.31 |
BandWidth | 60.93 |
MACD Line | -0.19 |
MACD Signal Line | -0.07 |
MACD Histogram | -0.112 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.24 | ||||
Resistance 3 (R3) | 4.22 | 4.12 | 4.20 | ||
Resistance 2 (R2) | 4.12 | 4.06 | 4.13 | 4.19 | |
Resistance 1 (R1) | 4.06 | 4.02 | 4.09 | 4.08 | 4.17 |
Pivot Point | 3.96 | 3.96 | 3.98 | 3.97 | 3.96 |
Support 1 (S1) | 3.90 | 3.90 | 3.93 | 3.92 | 3.83 |
Support 2 (S2) | 3.80 | 3.86 | 3.81 | 3.81 | |
Support 3 (S3) | 3.74 | 3.80 | 3.80 | ||
Support 4 (S4) | 3.76 |